President Donald Trump announced nine new drug companies joined his pricing plan on Monday. These firms agreed to lower costs for American patients in the Oval Office. The new deals bring the total to 26 companies covering 89 percent of the branded drug market. This move targets the gap where U.S. patients pay nearly three times more than others abroad.
The list includes Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB, according to Breitbart. Access to prices linked with other developed nations will be granted to state Medicaid programs by each firm. Trump said the idea has been sought for years. He noted that other presidents may not even have tried such a plan.
Health and Human Services Secretary Robert F. Kennedy Jr. shared the scope of this expansion. He declared that the day marks a total of 26 companies which have now finalized agreements with us. Nine out of 10 drugs utilized by Americans fall under the scope of these agreements. The White House projects these deals will save billions for families across the nation.
.@POTUS announces a major expansion of his Most Favored Nation drug pricing initiative — with nine new pharmaceutical companies committing to deliver their lowest drug prices for American patients. pic.twitter.com/hNoPACjnVk
— Rapid Response 47 (@RapidResponse47) August 31, 2026
The agreements cover medicines for serious conditions like Parkinson’s disease, hemophilia, and various forms of cancer. They also include treatments for macular degeneration, glaucoma, liver disease, and skin conditions. Per reports, all new innovative medicines these companies launch will have the same pricing framework.
Beyond lower prices, these nine companies committed at least $19.6 billion in near-term U.S. manufacturing investment. Certain companies are also contributing ingredient donations to the Strategic Active Pharmaceutical Ingredients Reserve. UCB will contribute 163 tons of levetiracetam to help control seizures. Sun Pharma will provide 71.4 tons of clindamycin and 6.75 tons of doxycycline for bacterial infections.
Teva Pharmaceuticals will supply 45 metric tons of metronidazole and 4.8 tons of amlodipine. Astellas will add 25 kg of tacrolimus to prevent organ rejection. These specific donations ensure the U.S. has vital supplies on hand. The deals mark the 18th through 26th agreements Trump secured since last fall.
The pressure to close the price gap comes from a credible threat of 100 percent tariffs. This approach got Pfizer to the table first and kept the deals coming. The government is using national security laws to force these changes. It is a direct move to stop foreign nations from undercutting American manufacturing.
Other major firms like Eli Lilly, Johnson & Johnson, and Merck have already agreed to similar terms. The goal is to ensure every state Medicaid program gets the best possible rates. This is not just about numbers on a page. It is about putting cash back in the pockets of hardworking families.
Trump said, “Nine new pharmaceutical companies are committing to deliver their lowest drug prices for American patients.” The list of covered drugs grows longer with each new agreement. The focus remains on making sure no American pays more than necessary for their health. This push covers nearly the entire market for branded drugs used today.
